Precision Biopsy, LLC

Precision Biopsy, LLC was formed in partnership with Allied Minds to develop and commercialize novel technology for the accurate diagnosis of prostate cancer. The company's diagnostic technology uses advanced spectroscopy imaging techniques in combination with tissue biopsy. For the first time, this unique ability will eliminate random prostate biopsies that are subject to sampling errors and can lead to inaccurate grading and staging of the disease. The scientific founders, professors Priya Werahara and John Daily of the University of Colorado, have long studied the morphology of cancer tissue. Combining their knowledge of advanced spectroscopy techniques has resulted in the ability to image the precise location of cancer in the prostate. Precision Biopsy, LLC is a subsidiary of Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company. More information about Allied Minds can be found at www.alliedminds.com

• Employees 11
• Founded 2008
• Annual Revenue $2200000
• Total Funding $38600000